Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

65.30 USD +0.41 (+0.63%)
Official Closing Price Updated: 7:59 PM EDT, Apr 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,654,000
Open 64.97
Bid (Size) 64.95 (6)
Ask (Size) 65.30 (2)
Prev. Close 64.89
Today's Range 64.83 - 66.17
52wk Range 56.56 - 85.79
Shares Outstanding 1,257,000,000
Dividend Yield 4.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Almost 1/3 of Patients in Pivotal TROPHY Study Responded to Treatment 
From PR Newswire
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult... 
From Business Wire News Releases

Performance

YTD
+8.63%
+8.63%
1 Month
+3.54%
+3.54%
3 Month
+6.11%
+6.11%
6 Month
+1.95%
+1.95%
1 Year
-16.01%
-16.01%

More News

Read More
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metasta
From PR Newswire
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products
From PR Newswire
IBB, AMGN, GILD, ILMN: Large Outflows Detected at ETF
Tags ETFs
From ETF Channel
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
From Business Wire News Releases
Cancer Biotech Tango Therapeutics Picks Boxer Capital's SPAC To Go Public Via $353M Merger
Tags Market News M&A IPOs
From Benzinga
A Peek Into The Markets: US Stock Futures Edge Higher; Bank Earnings In Focus
Tags Pre/Market Outlook Market News BRKR
From Benzinga
Drugmakers Are Vying for a Multibillion-Dollar Market
Tags GLPG Market News GILD
From Motley Fool
Notable Monday Option Activity: FAST, GILD, WMT
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.